Summary:
The SECARA study represents a joint effort – uniting researchers, doctors, and patients – to help advance research into an investigational drug for people with moderate to severe rheumatoid arthritis (RA). It is evaluating the safety and efficacy of an investigational drug in providing symptom relief.
The investigational drug is designed to block a protein (called cadherin-11) that promotes inflammation and damages joints. Researchers believe that the investigational drug, taken in combination with current treatment, may help reduce the inflammation that causes RA pain and joint damage.
You may be eligible to participate if you:
- have moderate to severe RA
- have active RA symptoms (tender and swollen joints, pain, stiffness, etc.)
- are taking methotrexate
- are taking one of following biologic drugs: Cimzia®, Enbrel®, Humira®, or Simponi®
If you qualify and choose to participate, you will remain on your current treatment while taking part in the study.
All study participants will receive the following at no cost:
- Investigational drug or placebo
- Study-related care, disease monitoring, and clinic visits
- Optional extension period with investigational drug
Travel Support
Participants may be provided with travel support and reimbursed for certain travel-related expenses.
Optional Extension Period with Investigational Drug
All participants will be given the opportunity to enter a 3-month extension period, during which they will:
- receive 3 doses of the investigational drug
- continue to receive study-related care, monitoring, and visits
During this period, travel support and reimbursement may be available.